Pulse Biosciences (NASDAQ:PLSE) Announces Earnings Results

Pulse Biosciences (NASDAQ:PLSE) posted its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01), Zacks reports. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.52 million. During the same period in the prior year, the business posted ($0.29) EPS. The company’s quarterly revenue was down 54.1% on a year-over-year basis.

Here are the key takeaways from Pulse Biosciences’ conference call:

• Pulse completed enrollment in its NANOPULSE-AF pivotal study with 169 evaluable patients, three months ahead of its original schedule. Patients are now in follow-up, with blended six- and 12-month results expected in Q3 2027.
• Preliminary PRECISE-BTN results showed that a single Vybrance treatment reduced thyroid nodule volume by more than 50% in 86% of patients, with a 78% average improvement in quality-of-life scores at six months and no serious adverse events reported. Further follow-up is due in 2027 and will support a planned 510(k) submission.
• The company ended the quarter with $189.2 million in cash and marketable securities, which management says provides roughly two years of runway; about $64 million of ATM capacity remains. It plans to use capital for clinical programs and manufacturing and commercial-launch preparation.
• Q3 revenue was just $395,000, while GAAP net loss widened to $23.1 million from $19.4 million a year earlier. Management expects quarterly non-GAAP costs and expenses to rise 15%–25% above the roughly $20 million average in Q2 and Q3 as clinical and pre-commercial investment increases.
• Pulse is preparing manufacturing capacity and market-launch plans for its nPulse catheter, targeting launch readiness beginning in early 2028 and remaining open to a partnership or other launch structure. However, strategic discussions have not produced a disclosed deal, and management said partners are waiting for further clinical and regulatory evidence.

Pulse Biosciences Price Performance

PLSE traded up $0.22 during midday trading on Friday, hitting $53.29. 428,197 shares of the company were exchanged, compared to its average volume of 373,557. The company’s 50 day simple moving average is $51.55 and its 200 day simple moving average is $32.28. Pulse Biosciences has a 1-year low of $12.56 and a 1-year high of $58.90.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PLSE. Canaccord Genuity Group boosted their price objective on shares of Pulse Biosciences from $58.00 to $74.00 and gave the company a “buy” rating in a report on Friday. Needham & Company LLC raised their target price on Pulse Biosciences from $58.00 to $64.00 and gave the stock a “buy” rating in a research note on Friday. BTIG Research initiated coverage on Pulse Biosciences in a research report on Wednesday, September 23rd. They set a “buy” rating and a $70.00 price target for the company. Mizuho set a $65.00 price target on Pulse Biosciences in a research note on Friday. Finally, Oppenheimer increased their price objective on Pulse Biosciences from $35.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $66.60.

Trending Headlines about Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Insider Activity

In related news, COO Liane Teplitsky bought 1,036 shares of the stock in a transaction dated Wednesday, August 26th. The shares were purchased at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the completion of the purchase, the chief operating officer directly owned 1,036 shares of the company’s stock, valued at $49,966.28. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders bought 4,095 shares of company stock valued at $199,931. Insiders own 74.00% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.